Search Results
Aug 31, 2026, 01:00 ET Samsung Biologics publishes prospectus for PolyPeptide public tender offer
broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S., and India. PolyPeptide's shares
More news about: Samsung Biologics
Aug 30, 2026, 06:15 ET Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
molecule dual agonist fixed-dose combination GLP-1/GIP (ASC30_48FDC), the first tirzepatide/eloralintide-like oral small molecule triple agonist fixed-dose combination GLP-1/GIP/amylin (ASC30_48_39FDC), and a fixed-dose combination of our small molecule oral GLP-1 and oral amylin (ASC30_39FDC).About
More news about: Ascletis Pharma Inc.
Aug 30, 2026, 06:15 ET 歌禮宣布每日一次口服小分子GLP-1受體激動劑ASC30用於長期體重管理的全球III期臨床項目完成首例受試者給藥
Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款每日一次口服小分子GLP-1R激動劑，用於長期體重管理和糖尿病治療；ASC30_48FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC48（GIPR激動劑）的固定劑量復方制劑；ASC30_48_39FDC，一款每日一次口服小分子三靶點激動劑，為ASC30（GLP-1R激動劑）、ASC48（GIPR激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC39，一款與eloralintide類似、強效的每日一次口服小分子胰澱素選擇性受體激動劑（SARA）；ASC30_39FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC36，一款胰澱素多肽，設計為每月一次至每季度一次皮下注射以及每日一次口服；ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FDC，一款每月一次皮下注射四靶點激動劑多肽，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲了解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Aug 29, 2026, 11:00 ET Meant Earns LegitScript Certification for Its Online GLP-1 Weight Care Platform
Aug. 29, 2026 /PRNewswire/ -- Meant has earned LegitScript certification for its online GLP-1 weight-care platform, a step that reinforces the transparency behind how the service connects patients with licensed U.S. clinical oversight,
More news about: Meant
Aug 28, 2026, 08:36 ET Choose Health Launches Most Comprehensive At-Home Liver Function Test with 20+ Biomarkers and Clinical Risk Scores
steatosis."We've been focused on liver health since 2018 because we saw this epidemic coming," said Holland. "With the rise of GLP-1 medications and awareness of metabolic health, now is the moment for consumers to take liver health as seriously as cholesterol or blood sugar."AvailabilityThe
More news about: Choose Health
Aug 28, 2026, 08:00 ET GLP-1 Users Are Spending Nearly 4x More on Fitness Than Other Consumers, New Report Finds
The headline finding: consumers taking GLP-1 medications spend $449 a month on fitness across categories, compared to $120 a month for non-usersGLP-1 users are more likely to pay for a gym membership (81 percent, against 43 percent
More news about: The Consumer Collective
Aug 28, 2026, 07:15 ET La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2
no fatales. Como el primer y único agonista receptor de GIP y GLP-1 aprobado por la FDA, Mounjaro es una molécula única que activa los receptores del cuerpo para GIP (polipéptido insulinotrópico dependiente de la insulina) y GLP-1 (agonista del receptor péptido 1 similar al glucagón). Acerca
More news about: Eli Lilly and Company
Aug 28, 2026, 07:00 ET FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
non-fatal stroke. As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).About Trulicity (dulaglutide)
More news about: Eli Lilly and Company
Aug 28, 2026, 06:02 ET 12 Press Releases You Need to See This Week
adults over age 55 with obesity according to a real-world studyFor adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lower costs translate into meaningful savings as early as 12 months into treatment. This is the first study of its kind in
More news about: PR Newswire
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers - GUTS
Fractyl's "REMAIN-1" study, evaluating Revita's efficacy in maintaining weight loss following the discontinuation of GLP-1 receptor agonist drug therapy. The REMAIN-1 study is designed to include three distinct patient cohorts: (i) the REVEAL-1 Cohort; (ii) the REMAIN-1
More news about: Pomerantz LLP
Aug 27, 2026, 10:07 ET SueWallSt Reminds Fractyl Health, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 20, 2026 - GUTS
including a September 26, 2025 announcement stating that Revita-treated patients "lost an additional 2.5% total body weight" after stopping GLP-1 drugs versus a 10% regain in sham-treated patients. As alleged, that pricing environment allowed the Company to sell 60 million shares
More news about: SueWallSt.com
Aug 27, 2026, 10:04 ET Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
homeostasis. Extensive preclinical and clinical studies have demonstrated that combining receptor-blocking antibodies targeting ACVR2A/2B with GLP-1-based weight loss therapies can further reduce body fat while effectively mitigating lean mass loss. In May 2026, the Company announced promising preclinical
More news about: Harbour BioMed
Aug 27, 2026, 09:00 ET Maven Members with High-Risk Pregnancies See 32% Fewer NICU Admissions
Through its consumer virtual clinic, Maven provides direct access to virtual care across 30+ specialties, as well as dedicated hormone and GLP-1 care programs purpose-built for women.Founded in 2014 by CEO Kate Ryder, Maven Clinic has raised more than $425 million from leading healthcare
More news about: Maven Clinic
Aug 27, 2026, 07:30 ET Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A
platform is expected to help businesses launch direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy ("TRT"), hair loss, skincare, sexual health and more. Hydreight
More news about: Hydreight Technologies Inc.
Aug 26, 2026, 10:09 ET GUTS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Fractyl Health, Inc. Securities Lawsuit - Contact Levi & Korsinsky
Fractyl Health told investors in September 2025 that Revita-treated patients lost an additional 2.5% of body weight after stopping GLP-1 drugs; four months later the Company reported 4.5% weight regain, and GUTS shares closed at $0.46.NEW YORK,
More news about: Levi & Korsinsky, LLP
Aug 26, 2026, 09:30 ET Cytrellis Launches ellacor® Micro-Coring® Technology for Full-Body Skin Resurfacing in Australia
demand for non-surgical procedures that address loose, crepey skin resulting from aging, weight loss, pregnancy, and the increasing use of GLP-1 medications."The ability to remove excess skin without surgery or thermal energy offers physicians an entirely new treatment option," said
More news about: Cytrellis Biosystems, Inc.
Aug 26, 2026, 06:45 ET Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
September 2025. Each Zepbound user was matched 1:1 with a control who met the same eligibility criteria but did not initiate any GLP-1 or GIP/GLP-1 receptor agonist medication. People were matched based on their baseline demographics, clinical characteristics, obesity-related complications
More news about: Eli Lilly and Company
Aug 25, 2026, 21:24 ET Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
popularity of GLP-1 receptor agonists, the global weight management markets are rapidly shifting towards a post-weight management era focused on "post-treatment maintenance," "body composition improvement," and "metabolic health." While current mainstream GLP-1 drugs effectively
More news about: Caliway Biopharmaceuticals
Aug 25, 2026, 10:15 ET Peptide Synthesis Market worth $1.54 billion by 2031 - Exclusive Report by MarketsandMarkets™
however, customers increasingly seek integrated solutions supporting complex, modified, cyclic, conjugated, and long peptides. Rising demand for GLP-1 and other therapeutic peptides is further increasing consumption of high-value building blocks and specialty reagents. At the same time, growing
More news about: MarketsandMarkets
Aug 25, 2026, 09:00 ET Monarch Expands Network of Premier OBGYNs with Dr. Kate White, Equipping Leading Women's Health Physicians with the Tools to Launch Independent Concierge Practices
more than 1 in 10 Americans are on a GLP-1. Her practice, Recalibrate Health, which is now open, also offers access to mental health counseling and nutrition services to provide well-rounded
More news about: Monarch
Aug 25, 2026, 07:30 ET Menu Transformation: Beverages Move from Add-Ons to Restaurant Growth Drivers
GLP-1 use, continue to reshape dining habits – beverages are increasingly serving as an affordable indulgence and a standalone occasion. The afternoon
More news about: National Restaurant Association
Aug 25, 2026, 06:15 ET Innovent Announces 2026 Interim Results and Business Updates
the end of 2025.At the same time, our next‑generation metabolic and obesity pipeline – including IBI3032 (once‑daily oral GLP‑1), IBI3042 (once‑weekly oral GLP‑1), IBI3040 (Amylin), IBI3046 (INHBE siRNA) and IBI3030 (monthly PCSK9‑GGG) – provides deep, long‑term growth reserves in global obesity
More news about: Innovent Biologics
Aug 25, 2026, 04:00 ET Sentante takes physical AI to market, beginning commercial rollout in vascular surgery and interventional radiology
2025.The rollout follows a year of clinical validation, including a world-first transatlantic remote thrombectomy on perfused human cadaver models and a GLP animal study of 24 remote procedures conducted across three continents. Sentante has integrated the NVIDIA Jetson AGX platform into its latest-generation
More news about: Sentante
Aug 24, 2026, 10:00 ET Zywave 2026 Midyear Market Outlooks: Agentic AI a Defining Force in Shaping Coverage, Benefits, and Workforce Strategy
Benefits Midyear Market Outlook covers rising healthcare costs, ERISA fiduciary litigation, AI's growing role in benefits administration and GLP-1 trends. The
More news about: Zywave
Aug 24, 2026, 10:00 ET OrangeTwist National Med‑Spa Announces Launch of Two New Non‑Surgical Skin‑Tightening Treatments, Expanding Innovation Across All 24 Centers
laxity, contour, and overall skin resilience without surgery or downtime. As more clients navigate skin laxity linked to rapid weight loss from GLP-1 medications, along with the visible effects of "tech neck" from daily screen time, these treatments offer a timely, non-invasive solution to address
More news about: OrangeTwist